Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499792 | 0.81 | CA1 (0.75) | CA1CA2CA4CA12CA9 | |
| SCHEMBL7687241 | 0.79 | MAPT (0.62) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL2562508 | 0.78 | LMNA (0.65) | ALDH1A1MAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL7363709 | 0.77 | ALDH1A1 (0.66) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL4365925 | 0.77 | HDAC1 (0.65) | MAPTSMN1; SMN2CA1CA2CA4 | |
| SCHEMBL31570085 | 0.77 | MAPT (0.64) | ALDH1A1MAPTNPC1SMN1; SMN2CA1 | |
| SCHEMBL925339 | 0.77 | MAPT (0.64) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL8278401 | 0.75 | MAPT (0.62) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL20543330 | 0.75 | MAPT (0.72) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL17475956 | 0.75 | MAPT (0.62) | ALDH1A1MAPTNPC1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060275213-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-12-07 | — | — | US | disclosed |
| EP-1549669-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060275213-A1 | Tumor targeting agents and uses thereof | CCL2, CCL5, SCTR | ALDH1A1 4626/4885MAPT 4644/4885NPC1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.